PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer
暂无分享,去创建一个
H. Klocker | G. Kristiansen | D. Dietrich | G. V. van Leenders | Z. Culig | M. Puhr | A. Eigentler | Z Culig | H Klocker | J. Hoefer | B. Uhl | M. Hoogland | F. Handle | B. Schlick | H. Neuwirt | V. Sailer | M Puhr | J Hoefer | A Eigentler | D Dietrich | G van Leenders | B Uhl | M Hoogland | F Handle | B Schlick | H Neuwirt | V Sailer | G Kristiansen
[1] J. Rao,et al. PIAS1 Regulates Breast Tumorigenesis through Selective Epigenetic Gene Silencing , 2014, PloS one.
[2] R. Geney,et al. Overcoming Multidrug Resistance in Taxane Chemotherapy , 2002, Clinical chemistry and laboratory medicine.
[3] G. Bartsch,et al. The androgen receptor pathway is by‐passed in prostate cancer cells generated after prolonged treatment with bicalutamide , 2006, The Prostate.
[4] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[5] H. Klocker,et al. Anterior gradient 2 and 3 – two prototype androgen‐responsive genes transcriptionally upregulated by androgens and by oestrogens in prostate cancer cells , 2013, The FEBS journal.
[6] U. Nagele,et al. Latent hypothyreosis as a clinical biomarker for therapy response under abiraterone acetate therapy. , 2014, Anticancer research.
[7] Rong-Gang Li,et al. Akt SUMOylation regulates cell proliferation and tumorigenesis. , 2013, Cancer research.
[8] D. Feldman,et al. The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.
[9] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[10] H. Klocker,et al. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] J. Palvimo,et al. PIAS proteins: pleiotropic interactors associated with SUMO , 2009, Cellular and Molecular Life Sciences.
[12] Marjo Malinen,et al. SUMOylation modulates the transcriptional activity of androgen receptor in a target gene and pathway selective manner , 2014, Nucleic acids research.
[13] P. Nelson,et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. , 2012, Cancer research.
[14] H. Klocker,et al. PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells , 2014, Oncotarget.
[15] K. Silverstein,et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. , 2013, Cancer research.
[16] F. Saad,et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.
[17] S. Geley,et al. Cyclin-Dependent Kinase 16/PCTAIRE Kinase 1 Is Activated by Cyclin Y and Is Essential for Spermatogenesis , 2011, Molecular and Cellular Biology.
[18] E. Wiemer,et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. , 2013, European journal of cancer.
[19] D. Tindall,et al. Posttranslational Modification of the Androgen Receptor in Prostate Cancer , 2013, International journal of molecular sciences.
[20] J. Palvimo,et al. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[21] L. Kenner,et al. Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. , 2009, Cancer research.
[22] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[23] Zhe Zhang,et al. Clinical activity of enzalutamide in Docetaxel‐naïve and Docetaxel‐pretreated patients with metastatic castration‐resistant prostate cancer , 2014, The Prostate.
[24] Zhiyong Guo,et al. Regulation of androgen receptor activity by tyrosine phosphorylation. , 2006, Cancer cell.
[25] H. Klocker,et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. , 2012, The American journal of pathology.
[26] M. Gross,et al. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells , 2001, Oncogene.
[27] S. Müller,et al. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[28] O. Jänne,et al. SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin , 2014, Nucleic acids research.
[29] D. Tindall,et al. Androgen modulation of coregulator expression in prostate cancer cells. , 2009, Molecular endocrinology.
[30] Ville Paakinaho,et al. Dynamic SUMOylation Is Linked to the Activity Cycles of Androgen Receptor in the Cell Nucleus , 2012, Molecular and Cellular Biology.
[31] G. Jenster,et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer , 2012, Modern Pathology.
[32] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[33] Seamus J. Martin,et al. PIAS-1 Is a Checkpoint Regulator Which Affects Exit from G1 and G2 by Sumoylation of p73 , 2004, Molecular and Cellular Biology.
[34] A. Sharrocks. PIAS proteins and transcriptional regulation--more than just SUMO E3 ligases? , 2006, Genes & development.
[35] H. Klocker,et al. PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. , 2012, The American journal of pathology.
[36] R. Kanaar,et al. Activation of the SUMO modification system is required for the accumulation of RAD51 at sites of DNA damage , 2013, Journal of Cell Science.
[37] H. Yasuda,et al. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. , 2001, Molecular cell.
[38] S. Jackson,et al. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks , 2009, Nature.
[39] Bart Barlogie,et al. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. , 2010, Blood.